Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Naltrexone Implants in Alcohol Use Disorders
NCT05919017Phase 1Unknown
- Sponsor
- Shenzhen Sciencare Medical Industries Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naltrexone in alcohol use disorder (AUD) (3 arms), sponsored by Shenzhen Sciencare Medical Industries Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 168 days and Area Under the Curve at 168 days. Status: unknown.
02
Drugs
naltrexone
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05919017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919017.